Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
During brain tumor surgery, it can be difficult for surgeons to distinguish between tumor tissue and healthy brain tissue. To address this challenge, fluorescent agents such as sodium fluorescein or 5-ALA are sometimes used. These substances cause the tumor to "glow" under specific lighting conditions, making it easier to visualize.
This study retrospectively analyzes medical records of patients treated at the University Hospital of Alessandria between June 2023 and March 2024. It compares surgeries performed with these fluorescent agents to those performed without them, in order to determine whether fluorescence-guided surgery leads to a higher rate of complete tumor removal (gross total resection), as confirmed by post-operative MRI scans.
The aim is to evaluate how the use of fluorescent dyes (fluorochromes) influences surgical outcomes in patients with high-grade gliomas (aggressive brain tumors). The study will also assess the impact of these tools on operative time, patient safety, and the overall recovery process.
High-grade gliomas are aggressive central nervous system tumors characterized by rapid growth and significant infiltration of the surrounding brain tissue. According to the European Association of Neuro-Oncology (EANO) guidelines, the standard of care involves a multimodal approach including surgery, radiotherapy, and chemotherapy. A key surgical goal is achieving Gross Total Resection (GTR), which is often limited by the difficulty of distinguishing tumor margins from functional brain structures.
Fluorescence-guided surgery (FGS), using fluorochromes such as sodium fluorescein (SF) and 5-aminolevulinic acid (5-ALA), has emerged as a valuable tool to enhance intraoperative tumor visualization.
This is a retrospective, observational, single-center study conducted at the Neurosurgery Unit of the Azienda Ospedaliero-Universitaria "SS Antonio e Biagio e Cesare Arrigo" in Alessandria. The primary objective is to evaluate the impact of fluorescence use on the extent of resection (EOR) in patients undergoing surgery for high-grade gliomas. The study compares surgical outcomes between procedures performed with and without the use of fluorescent tracers.
The study includes all patients who underwent surgery for suspected high-grade glioma (ICD-9 codes 191-191.9) between June 2023 and March 2024. Data are retrospectively extracted from electronic medical records, histopathological reports, surgical logs, and discharge summaries.
The extent of resection is assessed through comparative analysis of preoperative and postoperative magnetic resonance imaging (MRI) scans.
Secondary endpoints include: Characterization of epidemiological and clinical profiles, Comparison of preoperative and postoperative neurological status, Assessment of surgical safety and operative time,Identification of adverse effects and progression-free survival (PFS).
Descriptive statistics are used to summarize patient characteristics. Continuous variables are expressed as mean (standard deviation) or median (interquartile range), while categorical variables are presented as frequencies and percentages. Univariate analyses (Chi-square test, Fisher's exact test, or ANOVA) are performed to identify covariates for subsequent multivariate regression models. Statistical significance is set at p ≤ 0.05.
Data management is conducted using the REDCap (Research Electronic Data Capture) platform, ensuring compliance with GDPR and Italian data protection regulations.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fluorescence-Guided Surgery Group | This cohort includes patients who underwent neurosurgical resection with the aid of fluorescence-guided surgery. In these cases, fluorochromes (such as sodium fluorescein and/or 5-aminolevulinic acid [5-ALA]) were used to enhance intraoperative visualization of tumor tissue and facilitate its resection |
| |
| Conventional Surgery Group | This cohort includes patients who underwent neurosurgical tumor resection using standard microsurgical techniques without the use of fluorochromes. Tumor removal was performed based on anatomical and neuroradiological information and the surgeon's expertise, without fluorescence guidance. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| data collection | Other | Data are retrospectively extracted from electronic medical records, histopathological reports, surgical logs, and discharge summaries. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluate the extent of tumor mass resection | To evaluate the extent of tumor mass resection in patients undergoing surgery, based on the comparison of preoperative and postoperative magnetic resonance imaging (MRI) scans. | From preoperative MRI to immediate postoperative MRI |
| Measure | Description | Time Frame |
|---|---|---|
| Neurological Status | Comparison of patients' neurological status before and after surgery to assess the onset or worsening of neurological deficits using preoperative and intraoperative brain mapping, a set of procedures that allow a specific neurological function to be correlated with a specific area of the brain. | From preoperative assessment to immediate postoperative assessment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
A total of 45 patients undergoing surgery for high-grade brain glioma will be enrolled at the Azienda Ospedaliero-Universitaria "SS Antonio e Biagio e Cesare Arrigo" in Alessandria, during the period from June 2023 to March 2024.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Trial Center, Alessandria, Piedmont 151121 | Alessandria | Italy | 15121 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D005910 | Glioma |
| D005909 | Glioblastoma |
| D001932 | Brain Neoplasms |
| ID | Term |
|---|---|
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D003625 | Data Collection |
| ID | Term |
|---|---|
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
Not provided
Not provided
Not provided
Not provided
Not provided
| Patient Characteristic | Description of the baseline characteristics of patients undergoing neurosurgical resection for a brain lesion compatible with high-grade glioma, osservazione and clinical observation of patients during the postoperative hospital stay, with particular attention to the presence of early complications (early bleeding, surgical site infections, seizures) | From preoperative assessment to immediate postoperative assessment |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |
| D001254 | Astrocytoma |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |